TrialBritish journal of cancer2023

A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours.

Jayesh Desai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.